Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Retained Earnings (2016 - 2025)

China Pharma Holdings' Retained Earnings history spans 16 years, with the latest figure at -$47.2 million for Q4 2025.

  • For Q4 2025, Retained Earnings fell 7.24% year-over-year to -$47.2 million; the TTM value through Dec 2025 reached -$47.2 million, down 7.24%, while the annual FY2025 figure was -$47.2 million, 7.24% down from the prior year.
  • Retained Earnings reached -$47.2 million in Q4 2025 per CPHI's latest filing, down from $11.4 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $12.5 million in Q2 2021 to a low of -$47.2 million in Q4 2025.
  • Average Retained Earnings over 5 years is -$19.2 million, with a median of -$33.7 million recorded in 2022.
  • Peak YoY movement for Retained Earnings: skyrocketed 135.4% in 2023, then crashed 484.44% in 2024.
  • A 5-year view of Retained Earnings shows it stood at -$32.2 million in 2021, then dropped by 12.32% to -$36.2 million in 2022, then surged by 131.63% to $11.5 million in 2023, then plummeted by 484.44% to -$44.0 million in 2024, then fell by 7.24% to -$47.2 million in 2025.
  • Per Business Quant, the three most recent readings for CPHI's Retained Earnings are -$47.2 million (Q4 2025), $11.4 million (Q3 2025), and -$45.3 million (Q2 2025).